Top

Published in:

01-03-2014 | Review Article

Role of Microdialysis in Pharmacokinetics and Pharmacodynamics: Current Status and Future Directions

Authors: Francine Johansson Azeredo, Teresa Dalla Costa, Hartmut Derendorf

Published in: Clinical Pharmacokinetics | Issue 3/2014

Abstract

Diagnostic and therapeutic decisions in medical practice are still generally based on blood concentrations of drugs and/or biomolecules despite the knowledge that biochemical events and pharmacological effects usually take place in tissue rather than in the bloodstream. Microdialysis is a semi-invasive technique that is able to measure concentrations of the free, active drug or endogenous compounds in almost all human tissues and organs. It is currently being used to monitor brain metabolic processes and quantify tissue biomarkers, and determine transdermal drug distribution and tissue pharmacokinetics, confirming its importance as a widely used sampling technique in clinical drug monitoring and drug development as well as therapy and disease follow-up, contributing to rationalizing drug dosing regimens and influencing the clinical decision-making process.

Ungerstedt U, Pycock C. Functional correlates of dopamine neurotransmission. Bull Schweiz Akad Med Wiss. 1974;30:44–55.PubMed

Plock N, Kloft C. Microdialysis—theoretical background and recent implementation in applied life-sciences. Eur J Pharm Sci. 2005;25:1–24.CrossRef

Muller M, De La Pena A, Derendorf H. Issues in pharmacokinetics and pharmacodynamics of anti-infective agents: distribution in tissue. Antimicrob Agents Chemother. 2004;48:1441–53.CrossRef

Johanssen MJ, Newman RA, Madden T. The use of microdialysis in pharmacokinetic and pharmacodynamic. Pharmacotherapy. 1997;17(3):464–81.

Chaurasia C, Müller M, Bashaw ED, et al. AAPS-FDA workshop white paper: microdialysis principles, application, and regulatory perspectives. J Clin Pharmacol. 2007;47:589–603.CrossRef

Ryan DM. Pharmacokinetics of antibiotics in natural and experimental superficial compartments in animals and humans. Antimicrob Chemother. 1993;31 Suppl. D:1–16.CrossRef

Huse DM, Schulman K, Orsini L, et al. Burden of illness in Parkinson’s disease. Mov Disord. 2005;20:1449–54.CrossRef

Hillered L, Vespa PM, Hovda DA. Translational neurochemical research in acute human brain injury: the current status and potential future for cerebral microdialysis. J Neurotrauma. 2005;22(1):3–41.CrossRef

Brunner M, Derendorf H. Clinical microdialysis: current applications and potential use in drug development. Trends Anal Chem. 2006;25(7):674–80.CrossRef

10.

Joukhadar C, Mueller M. Microdialysis: current applications in clinical pharmacokinetic studies and its potential role in the future. Clin Pharmacokinet. 2005;44(9):895–913.CrossRef

11.

Carrel T, Schmid ER, von Segesser L, et al. Perioperative assessment of the likelihood of infection of the lower respiratory tract after cardiac surgery. Thorac Cardiovasc Surg. 1991;39:85–8.CrossRef

12.

Brunner M, Pernersdorfer T, Mayer B, et al. Surgery and intensive care procedures affect the target site distribution of piperacillin. Crit Care Med. 2000;28:1754–9.CrossRef

13.

Joukhadar C, Frossard M, Mayer BX, et al. Impaired target site penetration of beta-lactams may account for therapeutic failure in patients with septic shock. Crit Care Med. 2001;29:385–91.CrossRef

14.

Hyatt JM, McKinnon PS, Zimmer GS, et al. The importance of pharmacokinetic/pharmacodynamics surrogate markers to outcome: focus on antibacterial agents. Clin Pharmacokinet. 1995;28:143–60.CrossRef

15.

Theuretzbacher U. Tissue penetration of antibacterial agents: how should this be incorporated into pharmacodynamic analyses? Curr Opin Pharmacol. 2007;7:498–504.CrossRef

16.

Mouton JW, Theuretzbacher U, Craig WA, et al. Tissue concentrations: do we ever learn? J Antimicrob Chemother. 2008;61:235–7.CrossRef

17.

Traunmueller F, Zeitlinger M, Zeleny P, et al. Pharmacokinetics of single- and multiple-dose oral clarithromycin in soft tissues determined by microdialysis. Antmicrob Agents Chemother. 2007;519(9):3185–9.CrossRef

18.

Hutschala D, Skhirtladze K, Kinstner C, et al. In vivo microdialysis to measure antibiotic penetration into soft tissue during cardiac surgery. Ann Thorac Surg. 2007;84:1605–10.CrossRef

19.

Barbour A, Schmidt S, Rout RW, et al. Soft tissue penetration of cefuroxime determined by clinical microdialysis in morbidly obese patients undergoing abdominal surgery. Int J Antimicrob Agents. 2009;34:231–5.CrossRef

20.

Hutschala D, Kinstner C, Skhirtladze K, et al. The impact of perioperative atelectasis on antibiotic penetration into lung tissue: an in vivo microdialysis study. J Intensive Care Med. 2008;34:1827–34.CrossRef

21.

Poeppl W, Zeitlinger M, Donath O, et al. Penetration of doripenem in human brain: an observational microdialysis study in patients with acute brain injury. Int J Antimicrob Agents. 2012;39:343–5.CrossRef

22.

Schmidt S, Barbour A, Sahre M, et al. PK/PD: new insights for antibacterial and antiviral applications. Curr Opin Pharmacol. 2008;8:549–56.CrossRef

23.

Jain RK. Delivery of molecular medicine to solid tumors. Science. 1996;271(5252):1079–80.CrossRef

24.

Zamboni WC, Houghton PJ, Hulstein JL, et al. Interpatient variability in bioavailability and pharmacokinetics of oral topotecan in children with relapsed solid tumors. Cancer Chemother Pharmacol. 1999;43:269–76.CrossRef

25.

Brunner M, Muller M. Microdialysis: an in vivo approach for measuring drug delivery in oncology. Eur J Clin Pharmacol. 2002;58(4):227–34.CrossRef

26.

Konings IR, Engels FK, Sleijfer S, et al. Application of prolonged microdialysis sampling in carboplatin-treated cancer patients. Cancer Chemother Pharmacol. 2009;64:509–16.CrossRef

27.

Konings IR, Sleijfer S, Mathijssen RH, et al. Increasing tumoral 5-fluorouracil concentrations during a 5-day continuous infusion: a microdialysis study. Cancer Chemother Pharmacol. 2011;67(5):1055–62.CrossRef

28.

Motl S, Zhuang Y, Waters CM, et al. Pharmacokinetic considerations in the treatment of CNS tumours. Clin Pharmacokinet. 2006;45:871–903.CrossRef

29.

Cecchelli R, Berezowski V, Lundquist S, et al. Modelling of the blood-brain barrier in drug discovery, development. Nat Rev Drug Discov. 2007;6:650–61.CrossRef

30.

Abbott N. Prediction of blood-brain barrier permeation in drug discovery from in vivo, in vitro, in silico models. Drug Discov Today Technol. 2004;1:407–16.CrossRef

31.

Muldoon LL, Soussain C, Jahnke K, et al. Chemotherapy delivery issues in central nervous system malignancy: a reality check. J Clin Oncol. 2007;25:2295–305.CrossRef

32.

Collins J, Dedrick R. Distributed model for drug delivery to CSF and brain tissue. Am J Physiol Regul Integr Comp Physiol. 1983;245(3):R303–10.CrossRef

33.

de Lange E, Danhof M. Considerations in the use of cerebrospinal fluid pharmacokinetics to predict brain target concentrations in the clinical setting: implications of the barriers between blood and brain. Clin Pharmacokinet. 2002;41(10):691–703.CrossRef

34.

Blakeley JO, Olson J, Grossman SA, et al. Effect of blood brain barrier permeability in recurrent high grade gliomas on the intratumoral pharmacokinetics of methotrexate: a microdialysis study. J Neurooncol. 2009;91:51–8.CrossRef

35.

Portnow J, Badie B, Chen M, et al. The neuropharmacokinetics of temozolomide in patients with resectable brain tumors: potential implication for the current approach to chemoradiation. Clin Cancer Res. 2009;15:7092–8.CrossRef

36.

Shah VP. Progress in methodologies for evaluating bioequivalence of topical formulations. Am J Clin Dermatol. 2001;2(5):275–80.CrossRef

37.

Au WL, Skinner MF, Benfeldt E, et al. Application of dermal microdialysis for the determination of bioavailability of clobetasol propionate applied to the skin of human subjects. Skin Pharmacol Physiol. 2012;25:17–24.CrossRef

38.

Ortiz PG, Hansen SH, Shah VP, et al. Are marketed topical metronidazole creams bioequivalent? Evaluation by in vivo microdialysis sampling and tape stripping methodology. Skin Pharmacol Physiol. 2011;24:44–53.CrossRef

39.

Tettey-Amlalo RNO, Kanfer I, Skinner MF, et al. Application of dermal microdialysis for the evaluation of bioequivalence of a ketoprofen topical gel. Eur J Pharm Sci. 2009;36:219–25.CrossRef

40.

Brunner M, Davies D, Martin W, et al. A new topical formulation enhances relative diclofenac bioavailability in healthy male subjects. Br J Clin Pharmacol. 2011;71(6):852–9.CrossRef

41.

Simmel F, Kirbs C, Erdogan Z, et al. Pilot investigation on long-term subcutaneous microdialysis: proof of principle in humans. AAPS J. 2013;15(1):95–103.CrossRef

42.

Ortiz PG, Hansen SH, Shah VP, et al. Impact of adult atopic dermatitis on topical drug penetration: assessment by cutaneous microdialysis and tape stripping. Acta Derm Venereol. 2009;89:33–8.CrossRef

43.

Ortiz PG, Hansen SH, Shah VP, et al. The effect of irritant dermatitis on cutaneous bioavailability of a metronidazole formulation investigated by microdialysis and dermatopharmacokinetic methods. Cont Derm. 2008;59(1):23–30.CrossRef

44.

Lonnroth P, Jansson PA, Smith U. A microdialysis method allowing characterization of intercellular water space in humans. Am J Physiol. 1987;253(2 Pt 1):E228–31.PubMed

45.

Blin O, Audebert C, Pitel S, et al. Effects of dimethylaminoethanol pyroglutamate (DMAE p-Glu) against memory deficits induced by scopolamine: evidence from preclinical and clinical studies. Psychopharmacology. 2009;207:201–12.CrossRef

46.

Olivecrona M, Rodling-Wahlstrom M, Naredi S, et al. Prostacyclin treatment in severe traumatic brain injury: a microdialysis and outcome study. J Neurotrauma. 2009;26:1251–62.CrossRef

47.

Brody DL, Magnoni S, Schwetye KE, et al. Amyloid-β dynamics correlate with neurological status in the injured human brain. Science. 2008;321(5893):1221–4.CrossRef

48.

Zsigmond P, Dernroth N, Kullman A, et al. Stereotactic microdialysis of the basal ganglia in Parkinson’s disease. J Neurosci Methods. 2012;207:17–22.CrossRef

49.

Feichtner F, Schaller R, Fercher A, et al. Microdialysis based device for continuous extravascular monitoring of blood glucose. Biomed Microdevices. 2010;12:399–407.CrossRef

50.

Rooyackers O, Blixt C, Mattsson P, Wernerman J. Continuous glucose monitoring by intravenous microdialysis. Acta Anaesthesiol Scand. 2010;54(7):841–7.CrossRef

51.

Helmark IC, Mikkelsen UR, Børglum J, et al. Exercise increases interleukin-10 levels in both intraarticularly and peri-synovially in patients with knee osteoarthritis: a randomized controlled trial. Arth Res Ther. 2010;12:R126–37.CrossRef

Title: Role of Microdialysis in Pharmacokinetics and Pharmacodynamics: Current Status and Future Directions
Authors: Francine Johansson Azeredo
Teresa Dalla Costa
Hartmut Derendorf
Publication date: 01-03-2014
Publisher: Springer International Publishing
Published in: Clinical Pharmacokinetics / Issue 3/2014
Print ISSN: 0312-5963
Electronic ISSN: 1179-1926
DOI: https://doi.org/10.1007/s40262-014-0131-8

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Role of Microdialysis in Pharmacokinetics and Pharmacodynamics: Current Status and Future Directions

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2014

Towards Quantitation of the Effects of Renal Impairment and Probenecid Inhibition on Kidney Uptake and Efflux Transporters, Using Physiologically Based Pharmacokinetic Modelling and Simulations

Pharmacokinetic and Pharmacodynamic Profile of Empagliflozin, a Sodium Glucose Co-Transporter 2 Inhibitor

How Accurate and Precise Are Limited Sampling Strategies in Estimating Exposure to Mycophenolic Acid in People with Autoimmune Disease?

Modelling the Sitagliptin Effect on Dipeptidyl Peptidase-4 Activity in Adults with Haematological Malignancies After Umbilical Cord Blood Haematopoietic Cell Transplantation

The Basel Cocktail for Simultaneous Phenotyping of Human Cytochrome P450 Isoforms in Plasma, Saliva and Dried Blood Spots

Predictive Value of CYP3A and ABCB1 Phenotyping Probes for the Pharmacokinetics of Sunitinib: the ClearSun Study